From: Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Responders | Non-responders | p* | |
---|---|---|---|
N | 35 | 35 | |
Male, N (%) | M 29 (82.9 %) | M 23 (65.7 %) | ns |
Age (years) | 50.3 ± 12.5 | 48.5 ± 11.0 | ns |
DiseaseDuration (years) | 17.9 ± 10.6 | 16.3 ± 9.3 | ns |
MTX intake, N (%) | 15 (42.9 %) | 12 (34.3 %) | ns |
Sulfasalazine, N (%) | 3 (8.6 %) | 5 (14.3 %) | ns |
Prednisone intake, N (%) | 5 (14.3 %) | 14 (40 %) | <0.005* |
Uveitis, N (%) | 1 (4.1 %) | 1 (4.1 %) | ns |
IBD, N (%) | 1 (4.1 %) | 0 | ns |
NSAIDS, N (%) | 29 (82.9 %) | 27 (77.1 %) | ns |
ESR (mm/H) | 21.5 ± 18.3 | 31.0 ± 25.1 | ns |
CRP (mg/dL) | 1.9 ± 1.6 | 1.7 ± 1.5 | ns |
BASDAI | 59.5 ± 15.3 | 59.9 ± 19.6 | ns |
BASFI | 47.1 ± 16.8 | 52.2 ± 25.1 | ns |
BASMI | 5.9 ± 1.3 | 5.4 ± 1.6 | ns |
VAS | 64.9 ± 16.9 | 62.9 ± 18.8 | ns |
VASg | 50.5 ± 21.4 | 61.1 ± 19.0 | 0.05* |